Future Pak submits proposals to acquire Theratechnologies
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on THTX:
Disclaimer & DisclosureReport an Issue
Theratechnologies Reports Strong Q1 2025 Growth
Theratechnologies' Earnings Call: Growth Amid Challenges
Theratechnologies Achieves Revenue Growth and Secures Key FDA Approvals in Q1 2025
Theratechnologies reports Q1 revenue $19.047M vs $16.247M last year
Theratechnologies sees FY25 revenue $80M-$83M
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off-the-shelf' T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today. Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here. Second Quarter 2025 Business Update Highlights On track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026. Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1. Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch. Strong support from leading clinical experts and sites; refined trial design and moving to operational readiness ahead of IND/CTA submission Financial highlights Total operating expenses amounted to MNOK 38.4 in Q2 2025, and MNOK 67.8 YTD. Total loss was MNOK 37.5 for the period and MNOK 66.0 YTD. Net negative cash flow from operations was MNOK 59.4 in Q2 2025, and net decrease in cash and cash equivalents, excluding currency effects, was MNOK 59.0 during Q2 2025. Cash and cash equivalents amounted to MNOK 76.0 as per 30 June 2025. The current cash is expected to give a financial runway into Q2 2026, slightly shortened from the previously guided 'through Q2 2026' due to some one-off cost elements mainly related to investment in the successful development of the TCR-NK manufacturing process. The expected financial runway reflects that the cash burn rate is forecasted to come down significantly from the Q2 2025 level. On 27 May 2025, Zelluna ASA issued 227,096 new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The quarterly report and presentation will be published at 07:00 CET on 20 August 2025, and will be publicly available on the Zelluna website. The Company will conduct a webcast at 09:00 CET the same day, and questions can be submitted throughout the event. The webcast will be archived for replay following the conference call. Link to webcast here. For further information, please see or contact: Namir Hassan, CEO, Zelluna ASAEmail: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASAEmail: +47 482 48632 About Zelluna ASA Zelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of 'off-the-shelf' T-cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used 'off-the-shelf' to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting 'off-the-shelf' TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through clinical development of TCR and cell-based therapies including marketed products. For more information, please visit This stock exchange announcement was published by Joachim Midttun, Financial Manager at Zelluna ASA, on 20 August 2025 at 07:00 CET. Attachments Zelluna-ASA-Q225-Report Zelluna-ASA-Q225-Presentation
Business Insider
6 hours ago
- Business Insider
FDA recommends Walmart recall certain Great Value raw frozen shrimp
Certain raw frozen shrimp products processed by PT. Bahari Makmur Sejati, doing business as BMS Foods, a company located in Indonesia, and sold at Walmart (WMT) stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. These products include the following product names, lot codes, and best by dates: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: 3/15/2027; Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: 3/15/2027 and Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: 3/15/2027. FDA is actively investigating reports of Cesium-137 contamination in shipping containers and frozen shrimp products processed by BMS Foods of Indonesia. The U.S. Customs & Border Protection alerted FDA to the detection of Cs-137 in shipping containers at four U.S. ports. FDA collected multiple samples for radionuclide analysis, with results confirming the presence of Cs-137 in one sample of breaded shrimp. All containers and product testing positive or alerting for Cs-137 have been denied entry into the country. The agency continues to coordinate with CBP to prevent any contaminated products from reaching consumers and is working with Indonesian seafood regulatory authorities to investigate the root cause of the contamination. Although testing to date has not confirmed the presence of contamination in any product in commerce, the product appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern. To date, FDA has learned that Walmart has received implicated raw frozen shrimp, imported after the date of first detection of Cs-137 by CBP, but from shipments that did not alert for Cs-137. FDA has recommended Walmart recall this product. Elevate Your Investing Strategy:
Axios
12 hours ago
- Axios
Potentially radioactive shrimp recalled at Walmarts in a dozen states
The Food and Drug Administration warned Tuesday against eating certain brands of shrimp because they might be, uh, radioactive. Why it matters: This is not your chance to develop amazing crustacean-based superpowers. Any prolonged exposure to radiation could cause sickness or even death. Driving the news: The FDA said Tuesday that certain types of Great Value raw frozen shrimp sold at Walmart may be contaminated with Cesium-137, a radioactive isotope. U.S. Customs and Border Protection initially told the FDA that Cesium-137 had been detected in containers at four different U.S. ports, the FDA said. The FDA then found the isotope in one sample of breaded shrimp. Indonesia's BMS Foods allegedly violated the Federal Food, Drug, and Cosmetic Act, the FDA said, because the product "appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern." Yes, but: No shrimp that tested positive for the radioactive isotope have entered the U.S. commerce supply, according to the FDA. All products from BMS are banned "from coming into the U.S. until the firm has resolved the conditions that gave rise to the appearance of the violation," the FDA said. Worth noting: The FDA oversees safety of both domestic and imported seafood. The agency seeks out any immediate or potential threats when assessing products for safety. Which Walmart shrimp products are radioactive? Zoom in: The FDA shared three Great Value products that should not be shared, eaten or served to others: Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: March 15, 2027 Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: March 15, 2027 Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: March 15, 2027 Context: These were sold at stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. Walmart told Axios in an email Tuesday that it recalled the product from impacted stores and customers who purchased the shrimp are eligible for a full refund. "The health and safety of our customers is always a top priority," Kelly Hellbusch, a Walmart spokesperson, said in a statement. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate." Symptoms of radiation from shrimp, Cesium-137 The FDA said the amount of Cesium-137 found in the shipment was low enough that it "would not pose an acute hazard to consumers." However, the warning "is a measure intended to reduce exposure to low-level radiation that could have health impacts with continued exposure over a long period of time," the FDA said. According to the Environmental Protection Agency, ingesting Cesium-137 can increase the risk of cancer. What to do with recalled Walmart shrimp
